Structures by: Zhou X. B.
Total: 7
Ivabradine hydrochloride hemihydrate
C27H37N2O5,Cl,0.5(H2O)
Acta Crystallographica Section C (2019) 75, 5 545-553
a=5.48740(10)Å b=43.4767(7)Å c=11.4892(2)Å
α=90° β=98.144(2)° γ=90°
Ivabradine hydrochloride tetrahydrate
C27H37N2O5,Cl,4(H2O)
Acta Crystallographica Section C (2019) 75, 5 545-553
a=8.6747(2)Å b=18.2437(5)Å c=38.6507(9)Å
α=90° β=90° γ=90°
C23H29ClFN3O4,H2O
C23H29ClFN3O4,H2O
Acta Crystallographica Section C (2018) 74, 6
a=12.3225(9)Å b=14.5183(8)Å c=13.8141(8)Å
α=90° β=98.361(2)° γ=90°
Regorafenib crystalline form I
C21H15ClF4N4O3
Acta Crystallographica Section C (2016) 72, 4 291-296
a=7.6972(4)Å b=24.3703(12)Å c=11.3580(7)Å
α=90.00° β=93.545(2)° γ=90.00°
Regorafenib monohydrate
C21H15ClF4N4O3,H2O
Acta Crystallographica Section C (2016) 72, 4 291-296
a=4.7783(2)Å b=21.9538(9)Å c=20.5581(8)Å
α=90.00° β=92.3410(10)° γ=90.00°
Vortioxetine
C18H22N2S
Acta crystallographica. Section E, Crystallographic communications (2015) 71, Pt 8 883-885
a=7.6160(4)Å b=8.3267(5)Å c=13.9011(7)Å
α=84.999(2)° β=77.6310(10)° γ=74.347(2)°
1-{2-[(2,4-Dimethylphenyl)sulfanyl]phenyl}piperazine methanol monosolvate
C18H22N2S,CH4O
Acta crystallographica. Section E, Crystallographic communications (2015) 71, Pt 8 883-885
a=13.2100(7)Å b=18.1500(9)Å c=8.1746(4)Å
α=90.00° β=104.378(2)° γ=90.00°